🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Renaissance Technologies (RenTech)’s SBRA Holdings & Trades

First Buy
Q2 2013
Duration Held
41 Quarters
Largest Add
Q4 2019
+939,979 Shares
Current Position
67,660 Shares
$1.28 M Value

Renaissance Technologies (RenTech)'s SBRA Position Overview

Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 67,660 shares of Sabra Health Care REIT, Inc. (SBRA) worth $1.28 M, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 41 quarters.

Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in SBRA, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2019, adding 939,979 shares. Largest reduction occurred in Q1 2019, reducing 1.24 M shares.

Analysis based on 13F filings available since 2013 Q2

Renaissance Technologies (RenTech)'s Sabra Health Care REIT (SBRA) Holding Value Over Time

Track share changes against reported price movement

Quarterly Sabra Health Care REIT (SBRA) Trades by Renaissance Technologies (RenTech)

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 -1.04 M Reduce 93.87% 67,660 $18.94
Q3 2025 -508,400 Reduce 31.54% 1.1 M $18.64
Q2 2025 +190,200 Add 13.38% 1.61 M $18.44
Q1 2025 +23,700 Add 1.70% 1.42 M $17.47
Q4 2024 -128,479 Reduce 8.42% 1.4 M $17.32
Q3 2024 +239,420 Add 18.60% 1.53 M $18.61
Q2 2024 +559,800 Add 76.95% 1.29 M $15.40
Q1 2024 +298,880 Add 69.73% 727,479 $14.77
Q4 2023 +341,699 Add 393.21% 428,599 $14.27
Q3 2023 +86,900 New Buy 86,900 $13.94
Q1 2023 -17,000 Sold Out 0 $0.00
Q4 2022 +17,000 New Buy 17,000 $0.01
Q2 2022 -476,979 Sold Out 0 $0.00
Q1 2022 +402,200 Add 537.85% 476,979 $14.89
Q4 2021 +41,199 Add 122.69% 74,779 $13.55
Q3 2021 -877,099 Reduce 96.31% 33,580 $14.71
Q2 2021 +12,100 Add 1.35% 910,679 $18.20
Q1 2021 +406,800 Add 82.72% 898,579 $17.36
Q4 2020 +194,300 Add 65.32% 491,779 $17.37
Q3 2020 +297,479 New Buy 297,479 $13.79
Q2 2020 -189,879 Sold Out 0 $0.00
Q1 2020 -750,100 Reduce 79.80% 189,879 $10.92
Q4 2019 +939,979 New Buy 939,979 $21.34
Q1 2019 -1.24 M Sold Out 0 $0.00
Q4 2018 +881,500 Add 248.96% 1.24 M $16.48
Q3 2018 +354,079 New Buy 354,079 $23.12
Q1 2018 -284,379 Sold Out 0 $0.00
Q4 2017 +16,800 Add 6.28% 284,379 $18.77
Q3 2017 +267,579 New Buy 267,579 $21.94
Q2 2016 -88,115 Sold Out 0 $0.00
Q1 2016 +88,115 New Buy 88,115 $20.09
Q3 2015 -65,815 Sold Out 0 $0.00
Q2 2015 -164,195 Reduce 71.39% 65,815 $25.74
Q1 2015 -15,005 Reduce 6.12% 230,010 $33.15
Q4 2014 +186,900 Add 321.60% 245,015 $30.37
Q3 2014 +2,000 Add 3.56% 58,115 $24.31
Q2 2014 +6,443 Add 12.97% 56,115 $28.71
Q1 2014 +49,672 New Buy 49,672 $27.88
Q4 2013 -31,715 Sold Out 0 $0.00
Q3 2013 -47,900 Reduce 60.16% 31,715 $23.02
Q2 2013 +79,615 Add 0.00% 79,615 $26.11

Renaissance Technologies (RenTech)'s Sabra Health Care REIT Investment FAQs

Renaissance Technologies (RenTech) first purchased Sabra Health Care REIT, Inc. (SBRA) in Q2 2013, acquiring 79,615 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Renaissance Technologies (RenTech) has held Sabra Health Care REIT, Inc. (SBRA) for 41 quarters since Q2 2013.

Renaissance Technologies (RenTech)'s largest addition to Sabra Health Care REIT, Inc. (SBRA) was in Q4 2019, adding 939,979 shares worth $20.06 M.

According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 67,660 shares of Sabra Health Care REIT, Inc. (SBRA), valued at approximately $1.28 M.

As of the Q4 2025 filing, Sabra Health Care REIT, Inc. (SBRA) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.

Renaissance Technologies (RenTech)'s peak holding in Sabra Health Care REIT, Inc. (SBRA) was 1,612,120 shares, as reported at the end of Q2 2025.